Hypermethylation of regulatory sequences at the locus of the a%-el glutathione S-trnsferase gene GSTPI was detected in 20 of 20 human prostatic carcinoma tissue specimens studied but not in normal tissues or prostatic tissues exhibiting benign hyperplasia. In addition, a striking decrease in GSTPI expression was found to accompany human prostatic MATERIALS AND METHODS Immunohistochemical Staiing for GSTP1. Formalin-fixed paraffin-embedded prostatic tissue sections were stained with anti-GSTP1 antiserum (1:100 dilution; Oncor) using an immunoperoxidase method (Vectastain ABC Kit; Vector Laboratories), with either 3,3'-diaminobenzidine (DAB) or 3-amino-9-ethylcarbazole (AEC) as the peroxidase substrate. As a control for the specificity of staining, tissue sections prepared from normal human liver and normal human kidney were also stained with the anti-GSTP1 antiserum. Each ofthe tissues exhibited the characteristic staining pattern previously described (14).
GSTP1 antibodies failed to detect the enzyme in 88 of 91 prostatic carcinomas analyzed. In vitro, GSTPI expression was limited to human prostatic cancer cell lines conting GSTPI alleles with hypomethylated promoter sequences; a human prostatic cancer cell line containing only hypermethylated GSTP1 promoter sequences did not express GSTPI mRNA or polypeptides. Methylation of cytidine nucleotides in GSTPI regulatory sequences constitutes the most common genomic alteration yet described for human prostate cancer.
Human cancer cells typically contain somatically altered genomes, characterized by mutation, amplification, or deletion of critical genes (1) . In addition, the DNA template from human cancer cells often displays somatic changes in DNA methylation (1) (2) (3) (4) (5) (6) (7) (8) . However, the precise role of abnormal DNA methylation in human tumorigenesis has not been established (2) (3) (4) (5) (6) (7) (8) . For human prostate cancer, the most commonly diagnosed cancer in men in the United States (9), we have found uniform somatic changes in DNA methylation at the locus of the glutathione S-transferase gene GSTPL. Glutathione S-transferases (GSTs; EC 2.5.1.18) catalyze intracellular detoxification reactions, including the inactivation of electrophilic carcinogens, by conjugating chemically reactive electrophiles to glutathione (10) (11) (12) . Human GSTs, encoded by several different genes at different loci, have been classified into four families, which have been referred to as a, p., x, and 0 (13) . We report here that most human prostate cancers fail to express the ir-class GST, and that regulatory sequences near the GSTPI gene, which encodes the human ir-class GST, appear to be commonly hypermethylated during prostatic carcinogenesis.
MATERIALS AND METHODS
Immunohistochemical Staiing for GSTP1. Formalin-fixed paraffin-embedded prostatic tissue sections were stained with anti-GSTP1 antiserum (1:100 dilution; Oncor) using an immunoperoxidase method (Vectastain ABC Kit; Vector Laboratories), with either 3,3'-diaminobenzidine (DAB) or 3-amino-9-ethylcarbazole (AEC) as the peroxidase substrate. As a control for the specificity of staining, tissue sections prepared from normal human liver and normal human kidney were also stained with the anti-GSTP1 antiserum. Each ofthe tissues exhibited the characteristic staining pattern previously described (14) .
Immunoblot Analysis for GSTP1 Polypeptides. Salinewashed cultured prostatic carcinoma cells (15) (16) (17) (18) (19) were collected by centrifugation at 14,000 x g for 10 min at room temperature and then lysed in a protein extraction buffer [2% SDS/101% (vol/vol) glycerol/10 mM dithiothreitol in 62 mM Tris'HCl, pH 7.8] by heating to 950C for 10 min. The DNA content of each cell extract was estimated by using a diphenylamine assay (20) . Equivalent extracts from each of the cultured cell lines were subjected to immunoblot analysis for GSTP1 and DNA topoisomerase I polypeptides, using specific antisera (rabbit anti-GSTP1 from Oncor; human antitopoisomerase I provided by W. C. Earnshaw, Johns Hopkins University) as previously described (21) .
Northern Blot Analyss for GSTPI mRNA. Total RNAs were extracted from cultured cells by the method of Chomczynski and Sacchi (22) and then quantitated by using an orcinol assay (23) . Purified RNAs (20 ug) were electrophoresed on 1.5% agarose gels in the presence of2.2 M formaldehyde, transferred to Zeta-Probe (Bio-Rad) filters, and then assessed for GSTPI and TOP] mRNA levels by hybridization with specific 32P-labeled cDNA probes (prepared using the Random Primers DNA Labeling System, GIBCO/BRL). Following hybridization at 50CC for 16 hr (in 50%o formamide/7% SDS/0.5% nonfat dry milk/heat-denatured salmon sperm DNA at 200 pg/ml/300 mM NaCl/2 mM EDTA/20 mM sodium phosphate, pH 7.4), blots were washed with 0.3x SSC (lx SSC is 150mM NaCl/15 mM sodium citrate, pH 7.0) and 0.3% SDS for 60 mi at 650C before being exposed to X-Omat AR (Kodak) film at -700C. Plasmid pGSTii1 containing the entire GSTPI coding sequence (24) was obtained from the American Type Culture Collection; plasmid phTOPl-D1 containing 704 bp of human TOP) cDNA (25) tissues, were dissected from resection specimens obtained from men treated for localized prostatic carcinoma by radical prostatectomy. For analysis of GSTPI promoter methylation, purified DNAs were digested first with HindIll and EcoRI and then extensively with the m5C-sensitive restriction endonuclease BssHII. Digested DNAs were then electrophoresed on agarose gels, transferred to Zeta-Probe (BioRad) membranes, and then hybridized with 32P-labeled GSTPI cDNA as previously described (26) .
RESULTS AND DISCUSSION
Many human cancers exhibit increased GSTP1 expression relative to their tissues of origin (28) . Surprisingly, we found that most prostatic cancers contained decreased levels of detectable GSTP1 polypeptides relative to normal prostatic tissue. To assess GSTPI expression in normal and neoplastic prostatic cells in vivo, we subjected tissue specimens to immunohistochemical staining using anti-GSTP1 antibodies ( Fig. 1 
D-F). Prostatic intraepithelial neoplasia (PIN)
has been proposed to represent a premalignant lesion (29) . Of interest, in some PIN lesions, many epithelial cells were also devoid of GSTP1 (Fig. 1C ).
To better understand GSTPI regulation in human prostate cancer, five established human prostatic carcinoma cell lines (15) (16) (17) (18) (19) were assessed for GSTP1 expression by immunoblot analysis for GSTP1 ( Fig. 2A) and by Northern blot analysis for GSTPI mRNA (Fig. 2B ). In accordance with the lack of GSTP1 expression by human prostatic cancers in vivo, immunoblot analysis failed to detect GSTP1 polypeptides in a protein extract prepared from LNCaP cells (Fig. 2A, lane 1) , and Northern blot analysis failed to detect GSTP1 mRNA in RNA recovered from the LNCaP cell line (Fig. 2B, lane 1) . In contrast, Du-145 cells, PC-3 cells, PPC cells, and Tsu-Prl cells contained abundant GSTP1 polypeptides and GSTP1 mRNA ( Fig. 2 A (32, 33) . The 400 nt lying immediately 5' of the transcriptional start site contain nearly 72% C and G nucleotides, with 41 CpG dinucleotides. Methylation of CpG dinucleotides in regulatory regions of mammalian genes has been frequently associated with diminished transcriptional activity (34) (35) (36) (37) (38) . To determine whether differences in GSTPI promoter methylation correlate with the differences in GSTPI expression detected in the human prostatic cancer cell lines, DNA from each of the cell lines was digested with the m5C-sensitive restriction enzyme BssHII and then subjected to Southern blot analysis using a GSTPI probe (Fig. 3 (39, 40) , complete digestion at a BssHII site was evident (not shown). In addition, the failure of BssHII to cut LNCaP GSTPI promoter DNA likely resulted from cytidine methylation and not from mutation at the BssHII recognition site, because GSTP1 promoter sequences amplified from LNCaP DNA by the polymerase chain reaction (PCR) were readily digested by BssHII (not shown). Furthermore, LNCaP GSTP1 regulatory sequences also failed to cut with the m5C-sensitive restriction enzymes Not I and Sac II, which recognize sites at -132 and -102 in the GSTPI promoter, respectively (not shown), indicating extensive methylation of cytidines in the GSTP1 regulatory region.
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While LNCaP cells, which did not express GSTP1 mRNA or polypeptides (Fig. 2 A and B, lanes 1) , contained only hypermethylated GSTP1 promoter sequences (Fig. 3B, lane  6) , Tsu-Prl cells, which expressed abundant GSTP1 mRNA and polypeptides (Fig. 2 A and B, lanes 5 ), appeared to contain only hypomethylated GSTPI promoter sequences (Fig. 3B, lane 10) . In addition, hypomethylated GSTP1 promoter sequences were detected in Du-145 cells, PC-3 cells, PPC cells, and Tsu-Prl cells (Fig. 3B, lanes 7-9) . Each of these cell lines also expressed abundant GSTP1 mRNA and polypeptides ( Fig. 2 A and B, lanes 2-4) , suggesting a strong correlation between GSTPI transcriptional activity and the presence ofhypomethylated GSTP1 promoter sequences. As has been proposed for some C+G-rich 5' regulatory sequences in other genes, the GSTPI promoter sequences may constitute a methylation-sensitive "CpG island" (41 (42) . Thus, to determine whether lack of GSTPI expression by human prostate cancer cells in vivo might be accompanied by hypermethylation of GSTP1 regulatory sequences, we undertook an analysis of GSTPI promoter methylation, using DNA isolated from a variety of normal tissues as well as from prostatic carcinomas.
GSTPI promoter hypermethylation has not, to the best of our knowledge, been previously described (43) . To ascertain whether GSTPI promoter hypermethylation occurs during normal physiologic cellular differentiation, DNA isolated from normal human tissues with different GSTPI expression patterns was subjected to Southern blot analysis following digestion with the m5C-sensitive restriction enzyme BssHII (Fig. 4) . No methylated GSTPI promoter sequences were detected in DNA isolated from normal prostate, seminal vesicle, esophagus, kidney, liver, lung, or spleen (Fig. 4A) . To assess whether hypermethylation of GSTPI promoter sequences arises during aging in normal prostatic cells, DNA prepared from normal prostate tissue specimens recovered from men of different ages was also analyzed (Fig. 4B) . Again, there was no evidence of GSTP1 promoter hypermethylation in any of the normal prostatic tissues.
To discover whether GSTP1 promoter hypermethylation occurs during prostatic carcinogenesis in vivo, Southern blot analyses were performed on BssHII-digested DNA isolated from human prostatic carcinoma specimens (Fig. 5) . Each of the prostate cancers studied displayed evidence of hypermethylation of promoter sequences in GSTPI alleles relative to matched control DNA prepared from normal tissues (Fig.  5 A and B (Fig. SC) . When Southern blots containing BssHIIdigested DNA samples were hybridized with a GSTPI probe, apparent hypermethylation of GSTPI promoter sequences was detected in each ofthe cancer specimens, but none ofthe BPH specimens (Fig. SC) . In one ofthe cases, DNA prepared from grossly normal prostatic tissue also appeared to contain GSTPI alleles with some methylated promoter sequences (Fig. SC, lane 10) . Whether this resulted from infiltration of grossly normal prostatic tissue by microscopic carcinoma containing methylated GSTPJ promoters, from GSTP1 promoter hypermethylation in prostatic intraepithelial neoplasia (PIN) lesions in the grossly normal prostatic tissue, or from GSTPI promoter hypermethylation in histologically normal prostatic epithelial cells has not been established. However, hypermethylation of GSTPI promoter DNA nonetheless appears specific to the process of neoplastic transformation in the prostate: normal prostatic tissues from men without prostate cancer did not contain detectable methylation of GSTPI regulatory sequences (Fig. 4B) .
All ofthedata collected in this study suggest (10) (11) (12) . Consistent with this role, inherited homozygosity for null GSTMJ alleles may confer an increased risk of cigarette smoke-related lung cancer (46) (47) (48) . In addition, overexpression of a ii-class GST in cultured cells has been shown to reduce toxicity after benzo[a]pyrene exposure (49) . An intriguing implication of the apparent methylation-inactivation of GSTPI expression associated with prostatic carcinogenesis is the hypothesis that some normal prostatic epithelial cells ight acquire an increased vulnerability to electrophilic carcinogens by virtue of containing abnormally methylated GSTP1 promoters. Abundant epidemiologic evidence supports a significant role for environmental factors both in prostatic carcinogenesis and in prostate cancer progression to a life-threatening disease (50) . Normal prostatic tissue appears to contain epithelial cells with diminished GSTP1 expression but hypomethylated GSTPI regulatory sequences. Perhaps, rare cells with hypermethylated GSTPI promoter sequences arise among these GSTP1-negative epithelial cells and undergo clonal expansion as a consequence ofcarcinogen exposure. Were this hypothesis true, a possible prostate cancer prevention strategy might be the therapeutic augmentation of GST activity by using GST inducers. Recent studies have identified several GST inducers which may be useful for such an approach (51) (52) (53) . We hope that further studies of GSTP1 regulation in normal and neoplastic prostatic epithelial cells will help engender several new diagnostic and treatment strategies for prostate cancer.
